摘要:
The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and the protein tyrosine phosphatase PTPMEG. The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
摘要:
This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.
摘要:
Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Other related methods include, but are not limited to, prevention and treatment of ADDL-related diseases, such as Alzheimer's disease, mild cognitive impairment, Down's syndrome, and the like, using compositions that inhibit, block, or otherwise interfere with ADDL binding to one or more receptors localized at the post-synaptic density of neuronal cells.
摘要:
The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and the protein tyrosine phosphatase PTPMEG. The present invention provides methods for screening a PTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
摘要:
The present invention relates to the identification of STEP being as involved in signaling pathways relating to psychotic diseases, including schizophrenia, and other disorders in which NMDA receptor dysfunction is implicated. The present invention provides methods for screening STEP inhibitors that modulate NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
摘要:
This invention provides a novel receptor expressed on neuronal cells in a developmentally-specific manner. Accordingly, this invention provides the amino acid sequences of selected portions of the receptor and polynucleotides encoding these portions as well as antibodies that bind to the polypeptide portions of the receptor. Compositions and methods for using the compositions are also provided.
摘要:
Disclosed herein are methods for the quantification of ADDL binding to neuronal cells, including, but not limited to, primary cultures of hippocampal neurons. The method identifies and selects neurons based on any means capable of distinguishing neuronal cells, including, but not limited to, MAP2 immunoreactivity, which ensures that glial cells are excluded from an ADDL binding analysis; antibodies selective for neuronal cell surface receptors and/or other surface markers; reagents specific for neuronal signalling markers present intracellularly; and the like. Furthermore, ADDL binding occurs in a sub-population of 16 DIV neurons and is heterogeneous in intensity among individual cells. Also, ADDL binding can be further specified and quantified by using additional markers. Additionally, the presence or absence of ADDL binding is used to identify, characterize, analyze, assess, and/or evaluate agents (e.g., including, but not limited to, small molecules, antibodies, chemical compounds, dietary components, environmental conditions, etc.) that modulate ADDL binding. Such modulation can be positive or negative, including, but not limited to, ADDL binding inhibition, either total inhibition or partial inhibition, and the like.
摘要:
The present invention relates to the identification of STEP being as involved in signaling pathways relating to psychotic diseases, including schizophrenia, and other disorders in which NMDA receptor dysfunction is implicated. The present invention provides methods for screening STEP inhibitors that modulate NMDA-R signaling. The present invention also provides methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.
摘要:
The present invention relates to the identification of a binding between NMDA receptor (NMDA-R) subunits and a serine/threonine protein phosphatase (PSTP), e.g., PP2A. The present invention provides methods for screening a PSTP agonist or antagonist that modulates NMDA-R signaling. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal NMDA-R signaling.